An invited Guest Editorial entitled “Give Cas a Chance,” by Fyodor Urnov, PhD, Director of Technology & Translation at the ...

Early study data from Wave Life Sciences suggests how editing RNA may yield viable medicines. Large and small drugmakers say ...

Take a bite out of our new issue, where we examine Africa’s forgotten crops and the secrets of fresh food.

Editas, one of the oldest CRISPR-focused biotechs, is pivoting again — to a sickle cell treatment that requires editing a ...

An editorial by Fyodor Urnov lays out the urgent case for major reform in the regulatory appraisal of clinical therapies involving CRISPR gene therapies.

Given this risk, we thought we'd take a look at whether CRISPR Therapeutics (NASDAQ:CRSP) shareholders should be worried ...

CRISPR technology allows for precise DNA modifications, holding promise for treating genetic disorders and revolutionizing ...

Editas Medicine (EDIT – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Jack Allen ...

EDT Cathie Wood’s ARK Investment bought 47.8K shares of Crispr Therapeutics (CRSP) today Published first on TheFly – the ...

Long non-coding RNAs represent a paradigm shift over the last two decades, as better scientific understanding of their ...

In a potential advance for melanoma patients, researchers at ChristianaCare's Gene Editing Institute have used CRISPR gene ...

AvenCell Therapeutics announced that it raised $115 million in a Series B round. The company is developing CAR-T therapies ...